MORI-BUILDING
18.2.2021 06:02:05 CET | Business Wire | Press release
Mori Building Co., Ltd., Japan’s leading urban landscape developer, announced today that it will partner with Aman, the operator of diverse world-class luxury hotels and resorts, in the Toranomon-Azabudai Urban Redevelopment Project, a massive urban renewal undertaking that will revitalize a large area of central Tokyo when completed in 2023. The two main outcomes of the partnership will be the branded residence Aman Residences, Tokyo and luxury hotel Janu Tokyo , Aman’s sister brand, marking the debut of the Janu brand in Japan.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210217006076/en/
Shingo Tsuji, President and CEO of Mori Building, said: “Tokyo must add to its magnetic power if it is to succeed in its competition with the world’s greatest cities. Mori Building is joining hands with Aman, which operates diverse world-class resorts, to provide a world-leading residential environment and hotel unlike anything ever seen in Tokyo, where people will achieve harmony with nature as well as connect with and inspire others through creativity. By realizing this new form of ‘urban wellness,’ Mori Building will enhance Tokyo's magnetic power.”
Vladislav Doronin, Chairman and CEO of Aman and Janu, said: “Launching our first urban Aman Residences in Japan is a milestone moment in the history of Aman and speaks to our brand’s close relationship and symbiosis with this country and its incredibly special culture. Working with leading developers Mori Building, and being part of the Toranomon-Azabudai project, will enable us to bring to life Aman’s fifth development within Japan, this time offering a permanent sanctuary for owners as well as exclusive access to the Aman lifestyle. Furthermore, it will provide the setting for Janu Tokyo. In this hub of culture and art, we want to connect guests to the heart of this vibrant community and offer a chance for creative expression.”
Aman Residences, Tokyo — incomparable urban residential experiences
Aman Residences, Tokyo will be located on floors 54–64 of the 330-meter A District Tower, will offer 91 hotel-branded residences with exclusive services, including a residents-only Aman Spa (some 1,400 m²). Aman’s signature hospitality—both warm and unassuming—will enable residents to enjoy extraordinarily peaceful lifestyles while overlooking the vibrant Tokyo metropolis. The Tower’s sophisticated architectural design is the masterful work of Pelli Clarke Pelli Architects (USA) and interior design has been crafted by Yabu Pushelberg (Canada).
Janu Tokyo — Aman’s sister brand debuts in Japan
Aman’s luxury hotel brand Janu will make its Japan debut with Janu Tokyo on floors 1–13 in the B-2 District Tower. The hotel is designed by Denniston (Malaysia) under the leadership of Jean-Michel Gathy. In addition to approx. 120 luxury rooms, all offering excellent views of a central square filled with lush greenery, Janu Tokyo will boast Japan’s largest spa (some 3,500 m²) with spa treatment and a fitness center, six restaurants, and a cafe and bars for leisure and business gatherings. Janu Tokyo will welcome guests from around the world.
About Aman
Aman was founded in 1988 with the vision of building a collection of intimate retreats with the unassuming, warm hospitality of a gracious private home. The first, Amanpuri (place of peace) in Phuket, Thailand, introduced the concept and, since then, Aman has grown to encompass 33 exquisitely serene hotels and resorts in 20 destinations across the world, with a further seven under construction. The next Aman to open will be Aman New York. In 2020, a new hotel brand, Janu - meaning ‘soul’ in Sanskrit was unveiled. Janu offers a unique take on hospitality where genuine human interaction, playful expression and social wellness are at the core of the experience. Janu aims to bring balance to the head and heart and rekindle the soul. Janu launches with three forthcoming hotels which are already under construction: Montenegro (2022), Al Ula in Saudi Arabia (2022) and Tokyo (2023), as well as a robust pipeline of future hotels.
About Mori Building
Mori Building is an innovative urban developer based in Tokyo. The company is committed to maximizing the magnetic power of cities by creating and nurturing safe, sustainable and cosmopolitan urban centers based on its unique Vertical Garden City concept of high-rise centers for business, education, leisure and residence. The concept is applied in the company’s many leading-edge projects, including ARK Hills, Roppongi Hills and Toranomon Hills in Tokyo and the Shanghai World Financial Center. Mori Building is also engaged in real estate leasing, project management and consultation. Please visit www.mori.co.jp/en
Related Links
Press release “Mori Building Unveils Massive Urban Regeneration Project In Central Tokyo” published on August 22, 2019:
https://www.mori.co.jp/en/img/article/190822.pdf
Toranomon-Azabudai Project Fact Book:
https://www.mori.co.jp/en/projects/toranomon_azabudai/img/fact_book.pdf
Toranomon-Azabudai Project Image Movie:
https://www.youtube.com/watch?v=5akVE7tWOto&feature=emb_logo
View source version on businesswire.com: https://www.businesswire.com/news/home/20210217006076/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 03:00:00 CEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 00:00:00 CEST | Press release
On average, about 75% of patients with scalp psoriasis treated with zasocitinib achieved clear or almost clear skin at week 16 Approximately 70% of patients with palmoplantar disease treated with zasocitinib achieved clear or almost clear skin at week 16 Zasocitinib demonstrated statistically significant improvements in Nail Psoriasis Severity Index (NAPSI) versus placebo Results reinforce the potential of zasocitinib to deliver rapid and durable skin clearance, including in the hardest-to-treat areas, in a convenient once-daily pill Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance16.7.2026 23:36:00 CEST | Press release
Debut transaction more than three times oversubscribed The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful plac
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 22:22:00 CEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom